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ABSTRACT In a model system employing Chinese ham-
ster V-79 cells, the DNA synthesis inhibitor 3'-azido-3'-
deoxythymidine (BW A509U, AZT) was shown to induce
genome-wide DNA hypermethylation, low-frequency silencing
of thymidine kinase (TK; EC 2.7.1.21) gene expression, and
resistance to AZT. Twenty-four hours of exposure of V-79 cells
to 150 ,uM AZT led to >2-fold enhancement of genomic
5-methylcytosine levels and produced TK- epimutants at a rate
-43-fold above background. Such AZT-induced TK- epimu-
tants were shown to be severely reduced in their capacity to
activate AZT to its proximate antiviral form, AZT 5'-
monophosphate, as compared with the TK+ parental cell line
from which they were derived. TK- clones isolated under these
conditions were shown to be 9- to 24-fold more resistant to the
cytotoxic effects of AZT than the parental TK+ cell line and
showed collateral resistance to 5-fluoro-2'-deoxyuridine. Three
of four TK- epimutants could be reactivated at very high
frequency (8-73%) to the TK+ AZT-sensitive phenotype by 24
hr of exposure to the demethylating agent 5-azadeoxycytidine
(5-azadC), implying that drug-induced DNA hypermethyla-
tion, rather than classical mutation, was involved in the
original gene-silencing event in these three clones. These
5-azadC-induced TK+ revertants concomitantly regained the
ability to metabolize AZT to its 5'-monophosphate. RNA slot
blot analyses indicated that the four AZT-induced TK- clones
expressed 8.9%, 15.6%, 17.8%, and 11.1% of the parental
level ofTK mRNA. The three clones that were reactivatable by
5-azadC showed reexpression of TK mRNA to levels 84.4%,
51.1%, and 80.0% that of the TK+ parental cell line. These
experiments show that one potential mechanism of drug resis-
tance involves drug-induced DNA hypermethylation and re-
sulting transcriptional inactivation of cellular genes whose
products are required for drug activation.
The usefulness of drugs used in the treatment of cancer and
chronic viral infections is frequently limited by the develop-
ment of clinical drug resistance (1-4). 3'-Azido-3'-
deoxythymidine (AZT) is a drug with potential anticancer and
proven antiviral activity. In a manner similar to the widely
used anticancer agent 1-j3-D-arabinofuranosylcytosine(araC), AZT is activated by cellular enzymes to its nucleotide
form and then incorporated into DNA during S phase, where
it terminates further chain elongation (5). As an experimental
anticancer agent, AZT is used to take advantage of a putative
overexpression of enzymes involved in DNA synthesis and
repair which may occur as one aspect of the development of
resistance to cisplatin (6-8). For example, DNA polymerase
(Pol) (3, which is primarily involved in the repair of damaged
DNA, is apparently less discriminating in its choice of
nucleotides than is Pol a, which conducts replicative DNA
synthesis with a much higher level of fidelity (9). Repair tracts
within cisplatin-resistant tumor cells expressing elevated
levels of Pol 3 may thus tend to be terminated by incorpo-
ration of AZT to a greater degree than would similarly
exposed normal host tissues (6-8). Similarly, cisplatin-
resistant tumors expressing elevated levels of thymidine
kinase (TK), the enzyme responsible for activating AZT to its
proximate cytotoxic form, would also be expected to show
enhanced sensitivity to AZT (6).
The potential for AZT as a cancer chemotherapy agent is
apparently not limited to tumors expressing resistance to
cisplatin. Thus, based upon a similar biochemical rationale,
phase I trials are underway studying AZT combined with
5-fluorouracil and leucovorin (10), and combinations ofAZT
and 5-fluorouracil, cisplatin, and methotrexate (11).
A strategy similar to that described above for circumven-
tion of resistance to cisplatin is involved in the use ofAZT to
limit human immunodeficiency virus type 1 (HIV-1) infec-
tion, since the HIV-1 reverse transcriptase (RT) is several
orders of magnitude less discriminating in its choice of
nucleotides than host Pol a (5, 9). Recent work on the
mechanism underlying the development of clinical resistance
to AZT during treatment of AIDS patients has focused upon
mutation of the RT gene of HIV-1 (3, 4). Such mutations are
thought to produce an alteration in the RT protein which
reduces the extent to which AZT may be used as a substrate
in the reverse transcription of the HIV-1 RNA genome into
DNA. This model is attractive, since the mutation rate within
RNA genomes is many orders of magnitude greater than that
within DNA genomes (12-16). Based upon analogy with
known mechanisms of resistance to closely related agents
such as araC (17), however, cell-mediated mechanisms of
acquired resistance to AZT may also exist and may play an
important role in the clinical pathobiology of long-term
exposure to AZT in both cancer and AIDS patients.
Drug-induced DNA hypermethylation occurs as part ofthe
cellular response to toxic drug exposures that inhibit DNA
synthesis (18-21). It was suggested that such drug-induced
DNA hypermethylation may be capable of silencing genes by
transcriptional inactivation and conferring upon cells resis-
tance to drugs requiring metabolic activation by the protein
encoded by the silenced gene (19-21). Drug-induced DNA
hypermethylation is not solely a tissue culture phenomenon,
since malignant cells isolated from cancer patients undergo-
ing in vivo exposure to cytotoxic chemotherapy agents (e.g.,
hydroxyurea, araC) were also found to have undergone
genome-wide DNA hypermethylation (21). In the present
work we show that resistance to AZT can occur by AZT-
induced DNA hypermethylation which transcriptionally in-
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activates the cellular TK gene, preventing metabolic activa-
tion of AZT to its proximate antiviral form, AZT 5'-
monophosphate (AZTMP). The AZT-resistant phenotype
was observed to be reversible in three of four TK- clones as
a result of exposure to the demethylating agent 5-aza-2'-
deoxycytidine (5-azadC), indicating an epigenetic rather than
mutational basis for this mechanism of acquired resistance to
AZT in these clones. Following Jeggo and Holliday (22), we
therefore refer to these hypermethylation-induced clones as
"epimutants." We propose that such drug-induced DNA
hypermethylation and the subsequent generation of epimu-
tants by potentially reversible gene-silencing events may be
an important mechanism of acquired resistance to any drug
requiring metabolic activation to elicit a therapeutic effect.
MATERIALS AND METHODS
Cell Culture. Chinese hamster V-79 cells were obtained
from Morgan Harris (University of California at Berkeley).
Both the TK- and TK+ parental cell lines were maintained in
Dulbecco's modified Eagle's medium supplemented with
10% dialyzed fetal bovine serum.
Chemicals. Non-labeled AZT was kindly provided by
Kathy Pattishaw (Burroughs-Wellcome Research Laborato-
ries, Research Triangle Park, NC). [2-14C]AZT (51.4 mCi/
mmol, 0.6 mCi/ml in 2% aqueous ethanol; 1 mCi = 37 MBq)
and 5-azadC were purchased from Sigma. 5-Methyldeoxy-
cytidine 5'-triphosphate was purchased from Pharmacia.
Tissue culture media and other reagents were purchased from
Sigma, and fetal bovine serum was obtained from JRH
Biosciences (Lenexa, KS).
Analysis of DNA Hypermethylation. Cells in logarithmic
phase (2.5 x 105 per 60-mm tissue culture dish) were exposed
to the indicated concentrations of AZT for 48 hr in the
presence of [6-3H]uridine (1 ,uCi/ml; 50 Ci/mmol; ICN).
DNA 5-methylcytosine levels were quantitated as described
(20).
Quantitation ofTK Gene Silencing and Activation. Follow-
ing hypermethylating doses ofAZT (100 or 150 ,uM for 48 hr)
to TK+ parental V-79 cells, the level of TK gene silencing
events was quantitated by subsequent continuous exposure
to 5-bromo-2'-deoxyuridine (BrdUrd, 100 ,ug/ml). After 2
weeks of selection in BrdUrd, TK- clones were quantitated
with an Artek (Palo Alto, CA) automated colony counter. In
reactivation experiments, putative hypermethylation-
induced TK- epimutants were cloned, seeded into 75-cm2
tissue culture flasks at 106 cells per flask, and subsequently
exposed to 5 ,M 5-azadC for 24 hr. After removal of5-azadC,
cells were permitted to recover for 24 hr and then seeded into
60-mm tissue culture dishes at 103 cells per dish. Twenty-four
hours later, selection medium containing 1 x hypoxanthine/
aminopterin/thymidine (HAT; GIBCO) was substituted for
control medium, and cultures were subsequently changed
weekly into fresh HAT-containing medium. After 2 weeks of
selection, TK+ revertants were quantitated with an Artek
automated colony counter as described above.
Analysis of Acquired Resistance to AZT or 5-Fluoro-2'-
deoxyuridine (FdUrd). Cells in logarithmic phase (103 per
60-mm dish) were exposed to the indicated concentrations of
AZT for 48 hr or FdUrd for 24 hr, at which time drug was
removed, fresh culture medium was added, and clonal growth
was permitted to continue for an additional 2 weeks. At this
time, cultures were rinsed in phosphate-buffered saline fixed
in 100% methanol for 15 min, and stained in 0.4% (wt/vol)
Giemsa reagent for 15 min. Sensitivity to AZT or FdUrd was
then assayed using an Artek automated colony counter set at
a discrimination level of0.2mm and a sensitivity setting of76.
HPLC Analysis of AZT Nucleotide Pools. V-79 cells in log
phase (2.5 x 105 per 60-mm dish) were exposed to [2-14C]AZT
(1 ,Ci/ml) for 1 hr. After neutralization, trichloroacetic
acid-extracted nucleotide pools were directly injected onto a
Whatman SAX strong anion-exchange column and eluted
under the following conditions: 0-2 min, 90% solvent A/10%
solvent B; 2-20 min, a linear gradient to 90%o solvent B.
SolventA consisted ofdeionized ultrapure water, and solvent
B consisted of 1 M KH2PO4, pH 5.5. A Bio-Rad gradient-
module HPLC equipped with a model 1706 UV/visible
variable wavelength detector (detection performed at 254 nm)
was used to establish a flow rate of 1.5 ml/min at a pressure
of 80 kg/cm2. Fig. 1 shows the elution profile of nucleotide
pools extracted from [2-14C]AZT-pretreated V-79 cells. Ra-
dioactivity eluted as 5'-mono-, 5'-di-, and 5'-triphosphates
was quantitated by scintillation counting. The authenticity of
the putative AZTMP, AZTDP, and AZTTP was demon-
strated in a separate analysis in which fractions correspond-
ing to these metabolites were collected, hydrolyzed for 40
min at 180°C in 88% formic acid to liberate free thymine, and
analyzed by Aminex A-9 chromatography (20). Radioactivity
originally isolated as putative 5'-mono-, 5'-di-, and 5'-
triphosphate forms of AZT was shown to be coeluted with
free thymine, retaining the label originating at the 2-carbon of
the pyrimidine ring of AZT (Fig. 1 Inset). Thus, the radio-
activity that was eluted within the nucleoside 5'-mono-,
5'-di-, and 5'-triphosphate regions of the original column
procedure was shown to represent AZTMP, AZTDP, and
AZTTP. Endogenous ATP was used as an internal standard.
RESULTS
Fig. 2 illustrates two points: (i) AZT induced significant
enhancement of the level of genomic DNA methylation in
V-79 cells exposed to toxic concentrations ofthis drug and (ii)
this induction of DNA hypermethylation correlated with a
significant increase in the number of putative TK- epimu-
tants. Thus, a 2-fold increase in 5-methylcytosine content
correlated with a 43-fold increase in the number of putative
TK- epimutants produced. The background level of conver-
sion to the TK- phenotype was on the order of4 x 10-6. The
frequency of this phenomenon was thus increased to =2 x
10-4 following exposure to 150 ,uM AZT. When the number
ofTK- epimutants produced by exposure to AZT was plotted
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FIG. 1. HPLC analysis ofAZT nucleotide pools. TK+ V-79 cells,
TK- epimutants produced from them following hypermethylating
doses ofAZT, orTK+ revertants produced following exposure ofthe
TK- epimutants to 5-azadC were incubated for 1 hr with [2-14C]-
AZT, and nucleotide pools were extracted and analyzed. The elution
profile was as follows: 1, unmetabolized AZT plus glucuronidated
and other, undefined metabolites of AZT; 2, AZTMP; 3, AZT
5'-diphosphate (AZTDP); 4, adenosine 5'-diphosphate; 5, guanosine
5'-diphosphate; 6, uridine 5'-triphosphate; 7, AZT 5'-triphosphate
(AZTTP); 8, adenosine 5'-triphosphate; 9, guanosine 5'-triphos-
phate. (Inset) Radioactivity originating within the pyrimidine ring of
putative AZTMP, AZTDP, and AZTTP, following formic acid
hydrolysis to the free base, comigrates with thymine.
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FIG. 2. Correlation between level of AZT-induced DNA hyper-
methylation and induction ofTK- epimutants. For DNA hypermeth-
ylation studies, V-79 cells were exposed to the indicated concentra-
tions of AZT for 48 hr, in the presence of [6-3H]uridine (1 ,uCi/ml).
Results are expressed as the mean percent of control for four
independent determinations of 5-methylcytosine (SmC)/total cy-
tosine, ± SEM; control cells had levels of 5mC (% of total C) of 1.74
± 0.01. The background level of TK gene silencing, assumed to be
due to classical mutation, was -4 x 10-6. A total of 2 x 107 viable
cells were analyzed for each group. For induction of TK- epimu-
tants, V-79 cells were exposed to the indicated concentrations of
AZT for 48 hr, then replated at 105 viable cells per 60-mm dish.
Selection conditions for identification of TK- epimutants consisted
of continuous exposure to BrdUrd at 100 ,g/ml. Results are pre-
sented as the mean percent of control for 10 independent determi-
nations, ± SEM.
against the percent increase in DNA methylation (as com-
pared with controls) occurring in cultures exposed to 100 and
150 ,uM AZT, it was seen that the induction of TK- epimu-
tants was directly related to the degree of AZT-induced DNA
hypermethylation over the dose range studied (Fig. 1 Inset).
AZT-induced TK- clones 1-4 showed IC25 values of 122,
83, 190, and 128 ,M AZT, respectively, compared with an
IC25 value of 30 ,uM for the TK+ parental cell line from which
they were derived (Fig. 3). Upon challenge with 150 uM
AZT, clones 1-4 showed 9-, 11-, 24-, and 10-fold increases,
respectively, in resistance to AZT as compared with parental
TK+ cells (Fig. 3). Comparable increases in resistance to
FdUrd were observed in these clones (Fig. 4). Thus, clones
1 and 2 showed IC25 values for FdUrd of >5 ,AM; clone 3,
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FIG. 3. Resistance to AZT in hypermethylation-induced TK-
subclones and parental V-79 cells. Individual cultures (103 cells per
60-mm dish) were exposed to the indicated concentrations ofAZT for
48 hr, and viability was determined by quantitating clonogenic
capacity with an automated colony counter. The plating efficiency of
V-79 TK+ parental cells in medium without AZT in this series of
experiments was -89%. Results are presented as the mean of four
determinations, ± SEM. Where error bars are not apparent, SEM
values were smaller than the corresponding symbol. e, Clone 1; A,
clone 2; A, clone 3; o, clone 4; o, TK+ parental cells.
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FIG. 4. Resistance to FdUrd in hypermethylation-induced TK-
subclones and parental V-79 cells. Individual cultures (103 cells per
60-mm dish) were exposed to the indicated concentrations of FdUrd
for 24 hr, and viability was determined as for Fig. 3. The plating
efficiency of V-79 TK+ parental cells in this series of experiments in
medium without FdUrd was 88%. Results are expressed as the mean
of four determinations, ± SEM. Where error bars are not apparent,
SEM values were smaller than the corresponding symbol. Symbols
are as in Fig. 3.
-2.5 AM; and clone 4, -3 ,uM (compared with an IC25 of 0.7
AM for TK+ parental cells).
To be effective as an antitumor agent or as a chain
terminator for reverse transcription of HIV-i RNA genomes,
AZT must be activated to AZTMP by the product of the
cellular TK gene, and subsequently to AZTDP and AZTTP
by the product of the thymidylate kinase gene. It was thus
important for us to measure the capacity of our putative
AZT-induced TK- epimutants to activate AZT to its proxi-
mate antitumor/antiviral form, AZTMP, and to AZTDP and
AZTTP as well.
Nucleotide pool analysis (Fig. 5) showed that, with respect
to activation to AZTMP, hypermethylation-induced clones
showed levels corresponding to 4.2% (clone 1), 4.9% (clone
2), 0.8% (clone 3), and 0.6% (clone 4) of the parental TK+ cell
line from which they were derived. Total AZTDP and
AZTTP production was also reduced in the hypermethyla-
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FIG. 5. Ability of hypermethylation-induced clones to metabo-
lize AZT to its 5'-mono-, 5'-di-, and 5'-triphosphate forms. V-79 cell
cultures (2.5 x 105 cells per 60-mm dish) were exposed to [2-14C]AZT
(1 A,Ci/ml) for 1 hr, and nucleotide pools were extracted and
analyzed. Where error bars are not apparent, SEM values were
smaller than the corresponding symbol. Radioactivity (dpm) in
AZTMP, AZTDP, and AZTTP was as follows: TK+ parental cells,
39,264 ± 1102, 261 ± 15, and 495 ± 22, respectively; TK- clone 1,
1655 ± 143, 45 ± 4, and 59 ± 10, respectively; TK- clone 2, 1936 ±
120, 58 ± 6, and 96 ± 16, respectively; TK- clone 3, 319 ± 35, 14
± 2, and 17 ± 2, respectively; TK- clone 4, 226 ± 14, 24 ± 3, and
25 ± 4, respectively. ATP was used as an internal standard.
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tion-induced TK- epimutants, to levels of 17.2% and 12.0%
(clone 1); 22.3% and 19.6% (clone 2), 5.3% and 3.4% (clone
3), and 9.3% and 5.1% (clone 4). It is evident from these data
that the primary level of inhibition of AZT metabolism to its
antiviral form in our model system is at the level ofTK gene
expression, rather than thymidylate kinase gene expression,
because 5'-monophosphates represent a much smaller per-
centage of TK+ parental activity than do di- and triphos-
phates.
AZT induction of putative TK- epimutants might have
occurred via inactivation of the TK gene locus by classical
mutation, and not as a hypermethylation-mediated epigenetic
event. To test this possibility, each of the four isolated clones
was exposed to the demethylating agent 5-azadC. Exposure
to 5-azadC reactivated the TK+ phenotype in three ofthe four
clones with a frequency of 8-73% (Table 1). Clone 4 was not
reactivatable by 5-azadC, even after several attempts, sug-
gesting the possibility of a mutational basis for this TK gene
silencing event. This reversion frequency is many orders of
magnitude greater than that which could be expected as a
result of back mutation to the TK+ genotype. This suggests
strongly that the original gene silencing event involved meth-
ylation-mediated silencing of TK gene expression and not
classical mutation.
Transcriptional inactivation of the TK gene locus was
responsible for the induction of AZT-resistant TK- epimu-
tants (Table 2). AZT-resistant clones 1-4 showed 8.9%,
15.6%, 17.8%, and 11.1% of the TK-specific mRNA found in
an equivalent concentration (20 ,ug) of parental TK+ RNA.
Following exposure to 5-azadC, levels of TK mRNA in-
creased in the three revertible clones (nos. 1-3) to 84%, 51%,
and 80% of the original TK+ parental cell-line level. These
reactivation events represented increases in TK gene expres-
sion ranging from 3- to nearly 10-fold in the 5-azadC-induced
revertants compared with the AZT-induced TK- epimutants
from which they were derived.
All three 5-azadC-reactivated TK+ revertants showed a
substantial increase in their ability to metabolize AZT, rang-
ing from 3-fold to 34-fold at the 5'-monophosphate level,
2-fold to 15-fold at the diphosphate level, and zero to 2-fold
at the triphosphate level, as compared with the TK- epimu-
tants from which they were derived (Table 3). Here again, the
major change occurred at the monophosphate level rather
than at the di- or triphosphate level, suggesting that TK and
not thymidylate kinase represented the affected silenced (and
reactivated) gene in this model system.
DISCUSSION
Previous work demonstrated that drug-induced DNA hyper-
methylation constitutes one response of cells to cytotoxic
Table 1. Reactivation of TK+ phenotype following pulse
exposure to 5-azadC
Plating efficiency in HAT medium,
Clone % of TK+ parental cells
1 8±3
2 21 4
3 73±3
4 NR
TK- subclones 1-4 were exposed to a pulse dose of 5-azadC (5
,uM, 24 hr), and then selected for their ability to grow in HAT-
containing medium. Results obtained represent analysis of 104 cells
(ten 60-mm dishes containing 103 cells each) and are expressed as the
mean of five independent determinations of plating efficiency of
5-azadC-exposed cultures in HAT-containing medium, SEM. The
plating efficiency ofV-79 parental TK+ cells was -89%o, and colonies
enumerated in clones 1-3 ranged in numbers from 8 x 102 to 7 x 103.
NR, not reactivatable.
Table 2. mRNA expression in AZT-induced TK- epimutants
and in 5-azadC-induced TK+ revertants derived from them
mRNA, % of TK+ parental cells
AZT-induced 5-azadC-induced
Clone TK- epimutant TK+ revertant
1 8.9 84.4
2 15.6 51.1
3 17.8 80.0
4 11.1
Twenty micrograms of total RNA from each clone was blotted to
nylon membrane and probed with an oligolabeled fragment from the
3' end of the Chinese hamster V-79 TK gene. Densitometric scans of
the resulting films were quantitated by the method of peak heights.
The level ofTK mRNA expressed in the TK+ parental cell line was
taken as 100lo of the expected expression level, and the values given
above represent individual percentages of this level of expression.
Clone 4 was not reactivatable by 5-azadC. Measurements of log(rot)
indicated that the percent abundance of TK transcripts in the
unsynchronized TK+ parental cell line analyzed in logarithmic phase
was -0.5%.
levels ofDNA synthesis-inhibiting drugs, both in vitro and in
vivo (19-21). Since physiologic DNA methylation represents
one mechanism by which cells silence genes (23-26), such
drug-induced DNA hypermethylation may play a role in the
development of resistance to drugs requiring metabolic ac-
tivation (21). In the present work we observed that at
cytotoxic concentrations of AZT, a >2-fold enhancement in
total genomic DNA methylation occurred in V-79 cells,
concomitant with a 43-fold enhancement in the induction of
AZT-resistant, TK- subclones compared with nontreated
controls (Fig. 2). (Under the conditions reported here, AZT
resistance appeared to be primarily due to hypermethylation
inactivation of the TK gene, rather than to inactivation of
other genes whose protein products are also required forAZT
activation-e.g., thymidylate kinase.) The IC25 value for
AZT (Fig. 3) or FdUrd (Fig. 4) in these subclones was
substantially increased and within a range that would confer
drug resistance in vivo. Since three of four TK- AZT-
resistant subclones could be reactivated at high frequency for
TK+ expression and resensitization towards AZT by expo-
sure to the demethylating agent 5-azadC, the initial gene
silencing clearly was an epigenetic rather than a mutational
event in these three clones (Table 1).
Occurring concomitantly with their loss of sensitivity to
AZT or FdUrd, all drug-induced TK- epimutants lost their
ability to activate AZT to its proximate antitumor/antiviral
form, AZTMP (Fig. 5). 5-azadC-induced reversion to the
TK+ phenotype correlated directly with ability to reexpress
TK-specific mRNA (Table 2) and the ability to activate AZT
Table 3. Ability of 5-azadC-induced TK+ revertants to
metabolize AZT to its 5'-mono-, 5'-di-, and 5'-triphosphate forms
5-azadC- Fold increase over TK- epimutant
derived
revertant clone AZTMP AZTDP AZTTP
TK+1 3.0 ± 0.007 3.0 ± 0.21 1.2 ± 0.10
TK+2 2.5 ± 0.16 2.3 ± 0.00 0.9 ± 0.08
TK+3 33.9 ± 0.92 15.0 ± 0.81 2.0 ± 0.32
Cells were exposed to [2-14C]AZT for 1 hr, and nucleotide pools
were extracted and analyzed as described in the text. Results are
expressed as the mean of three independent determinations, ± SEM.
Radioactivity (cpm) in AZTMP, AZTDP, and AZTTP was as fol-
lows: TK+ 1, 4982 + 19, 135 + 13, and 255 + 28, respectively;
TK+ 2, 4910 ± 437, 133 ± 2, and 225 ± 27, respectively; TK+3,
11,475 ± 1057; 205 ± 17, and 470 ± 110, respectively. A nucleotide
concentration of 1.0 represents dpm from [2-14C]AZT in the respec-
tive mono-, di-, and triphosphate fractions of the TK- epimutant
from which the TK+ revertant was derived.
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to AZTMP (Table 3). This finding suggests that drug-induced
DNA hypermethylation occurring as part of the toxic re-
sponse to drug exposure mimics the negative transcriptional
regulation characteristic of physiologic DNA methylation.
It can be noted from Figs. 2 and 3 that AZT is relatively
nontoxic to V-79 cells, and very high levels of the drug
(100-150 ,uM) were required to induce the toxicity of which
DNA hypermethylation is a part. Drug-induced DNA hyper-
methylation very definitely is dependent upon toxic levels of
drug exposure (21). The levels of AZT used in our experi-
ments are thus above those that can be achieved clinically
(27). However, the human CD4+ T-lymphocyte populations
that are the target for AZT antiviral chemotherapy are much
more sensitive to AZT than are V-79 cells. In fact, it has been
demonstrated that human tissues in general are much more
sensitive to AZT than are rodent tissues (28). Further, with
respect to anticancer chemotherapy, enhanced sensitivity to
AZT might also be expected in human tumors expressing
resistance to cisplatin by virtue of overexpression of TK or
Pol genes (6-8). That epigenetic events are indeed involved
in establishing a drug-resistant state in vivo is supported by
studies showing that lymphocytic leukemia cells resistant to
araC, presumably by virtue of low expression of the required
activating enzyme, deoxycytidine kinase, can be reactivated
for deoxycytidine kinase expression and sensitivity to araC
by exposure of patients to the demethylating agent 5-azacy-
tidine (29). This example of an apparently methylation-
related silencing of deoxycytidine kinase resulting in araC
resistance in vivo bears striking similarity to TK gene silenc-
ing resulting in AZT resistance. Both drugs are false metab-
olites ofDNA precursors and require metabolic activation to
the nucleotide form for antitumor or antiviral action. Both
possess chain-termination properties once they are incorpo-
rated into DNA. Finally, resistance to both drugs can occur
by virtue of methylation silencing of the gene for the acti-
vating enzyme and can be reversed by exposure to demeth-
ylating agents. It therefore appears very likely that epigenetic
gene-silencing events similar to those observed in araC-
treated patients will also occur in patients undergoing anti-
cancer or antiviral chemotherapy with AZT.
Mutations within the HIV-1 RT gene may confer resistance
to AZT (3, 4). The extent to which cell-mediated resistance
to AZT contributes to the development of clinical resistance
to AZT, either alone or in concert with viral RT gene
mutations, remains to be determined. There is, however,
some precedent for suggesting that optimum conditions for
the development of RT gene mutations might exist within
CD4+ T lymphocytes that have a methylation-silenced TK
gene. Thus, in our hands, TK genes silenced by drug-induced
DNA hypermethylation appear not to be totally silent. As
illustrated in Fig. 5 and as observed by us in other experi-
ments using V-79 and other cell types, residual TK activity in
the range of 2-10o is common. Such limited activation of
AZT to its proximate antiviral form in hypermethylation-
silenced TK- epimutants may permit selective pressure
sufficient to encourage viral evolution toward AZT-resistant
subtypes, without being overtly lethal to the virus.
Finally, in order for AZT-induced DNA hypermethylation
to silence TK genes under conditions which permit cell
viability, repair of AZT-terminated replication intermediates
must occur. Such repair of AZT-terminated replication in-
termediates has been reported in mammalian cells (30).
Our results with the V-79 cell model system indicate that
drug-induced DNA hypermethylation may play a role in the
development of resistance to drugs requiring metabolic ac-
tivation to their anticancer/antiviral forms. The contribution
of such drug-induced DNA hypermethylation to in vivo drug
resistance and the possibility and effects of its circumvention
remain to be determined, however.
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